- Recent Funding
- Investors
- ATEM Capital Fund LP
ATEM Capital Fund LP portfolio
ATEM Capital Fund LP has 2 portfolio companies on record at Recent Funding.
About this page
Its most recent investment on record is Triumvira Immunologics's $45M Series A round in March 2022, alongside Multiple Myeloma Research Foundation, Leaps by Bayer, Myeloma Investment Fund and 2 others. By category, its portfolio leans toward Health and bio (2).
What ATEM Capital Fund LP invests in
- Health and bio · 2 · 100%
How ATEM Capital Fund LP invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $45M |
ATEM Capital Fund LP portfolio companies
TTriumvira Immunologics$45MSeries A · Mar 2022
PPGxAIbacker
| Company | Round with ATEM Capital Fund LP | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $45M | $100M | Mar 17, 2022 Series A |
Health and bio |
backer | undisclosed | Sep 14, 2026 Seed |
Most frequent co-investors
BB Capital1 shared round · last Mar 17, 2022
LLeaps by Bayer1 shared round · last Mar 17, 2022
NNorthpond Ventures1 shared round · last Mar 17, 2022
MMyeloma Investment Fund1 shared round · last Mar 17, 2022
MMultiple Myeloma Research Foundation1 shared round · last Mar 17, 2022
Similar investors
IIzou Partners2 companies · 2 deals in 12 mo
- TThe Ljungstrom Family Office2 companies · 2 deals in 12 mo
OO'Shaughnessy Ventures3 companies · 1 deal in 12 mo
SSide Stage Ventures3 companies
AAble Partners4 companies · 1 deal in 12 mo
GGenoa Ventures5 companies · 4 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Share is of the 1 round on Recent Funding that name ATEM Capital Fund LP. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists ATEM Capital Fund LP, which is a subset of its real portfolio. API: /api/v1/investors/atem-capital-fund-lp (get a free API key). More: the most active VC firms and new venture capital funds.